Yersinia Research Unit, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris, France.
Vaccine Programs, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris, France.
Vaccine. 2020 Feb 18;38(8):1888-1892. doi: 10.1016/j.vaccine.2020.01.014. Epub 2020 Jan 18.
A single oral inoculation to mice of the live attenuated Yersinia pseudotuberculosis VTnF1 strain producing an F1 pseudocapsule protects against bubonic and pneumonic plague. However oral vaccination can fail in humans exposed to frequent intestinal infections. We evaluated in mice the efficacy of subcutaneous vaccine injection as an alternative way to induce protective immunity, while reducing the dose and avoiding strain release in nature. A single subcutaneous dose of up to 10 CFU induced dose-dependent antibody production. At the dose of 10 CFU, i.e. 10 times less than via the oral route, it caused a modest skin reaction and protected 100% against bubonic and 80% against pneumonic plague, caused by high doses of Yersinia pestis. Bacteria migrating to lymph nodes and spleen, but not feces, were rapidly eliminated. Thus, subcutaneous injection of VTnF1 would represent a good alternative when dissemination in nature and human intestinal responsiveness are limitations.
单次口服接种产生 F1 假荚膜的减毒活耶尔森氏菌 VTnF1 菌株可预防鼠疫的败血型和肺鼠疫。然而，口服疫苗接种在经常发生肠道感染的人群中可能会失败。我们在小鼠中评估了皮下疫苗注射作为诱导保护性免疫的替代方法的功效，同时减少了剂量并避免了在自然界中的菌株释放。高达 10 CFU 的单次皮下剂量可诱导剂量依赖性抗体产生。在 10 CFU 的剂量下，即通过口服途径的 10 倍，它引起适度的皮肤反应，可 100%预防败血型鼠疫和 80%预防高剂量鼠疫耶尔森氏菌引起的肺鼠疫。迁移到淋巴结和脾脏的细菌，但不是粪便中的细菌，被迅速清除。因此，当在自然界中传播和人类肠道反应性受到限制时，皮下注射 VTnF1 将是一个很好的选择。
